Filters
New drug applications approved by US FDA as of 1-15 October 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
For survivors of colorectal cancer (CRC), consuming more fibre in their daily diet helps reduce bowel-related symptoms, according to a study.
Treatment with dapoxetine combined with nonpharmacological interventions is effective in improving sexual function in individuals with lifelong premature ejaculation (LPE), as shown in a study.
Metformin treatment prior to conception is associated with a reduced risk for severe nausea and vomiting during pregnancy, according to new research.
Acute dengue virus (DENV) infection appears to be associated with an increased likelihood of new-onset neurologic events, although the overall increase appears modest, according to a retrospective study from Singapore.
Gay men and bisexual individuals are more likely to have risky sexual behaviours and experience sexual victimization, sexual dysfunctions, and other adverse outcomes than lesbians, reports a Danish study.
Patients with cirrhosis using calcium channel blockers (CCBs) are not at increased risk of variceal haemorrhage, as reported in a retrospective study.
Treatment with telitacicept reduces proteinuria among patients with immunoglobulin A nephropathy (IgAN) compared with placebo, according to a phase III study presented at ASN Kidney Week 2025.
For individuals with persisting COVID-19 symptoms, a 3-month resistance exercise program appears to yield greater improvements in physical function and psychological well-being compared with usual care alone, as shown in a study.
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) results in a decrease in deaths and major adverse cardiovascular events (MACE) in high-risk patients, reports as study.
